Whitehawk Therapeutics, Inc. 2025 Annual Report: Key Highlights for Investors

Company Overview

Whitehawk Therapeutics, Inc. (Nasdaq: WHWK) is a pharmaceutical company incorporated in Delaware, focusing on life sciences and pharmaceutical preparations. The company is headquartered in Morristown, NJ, and operates in the field of developing advanced Antibody Drug Conjugate (ADC) therapies and other oncology assets. The company has undergone several name changes, previously known as Aadi Bioscience, Inc. and Aerpio Pharmaceuticals, Inc.

Key Report Highlights

• Annual Report Filing: The company filed its 10-K for the fiscal year ending December 31, 2025, with the SEC on March 12, 2026.
• Listed Security: Common stock, \$0.0001 par value per share, traded on Nasdaq under the symbol WHWK.
• Shares Outstanding: As of the report, 47,196,564 shares of common stock were outstanding.
• Issuer Status: Whitehawk is classified as a “smaller reporting company” and is not a well-known seasoned issuer nor an emerging growth company.
• Compliance: Whitehawk has complied with all SEC filing requirements and submitted all required interactive data files.

Forward-Looking Statements and Strategic Priorities

The report contains multiple forward-looking statements relating to the company’s operational and financial outlook. Investors should note:

• Capital Position: Management believes current cash, cash equivalents, and short-term investments are sufficient to fund operating expenses and capital expenditure requirements based on current plans. Additional funding needs may arise depending on the progression of ADC therapies or other development programs.
• Business Development: Whitehawk is actively pursuing strategic partnerships and transactions to expand its portfolio and maximize asset value. The company leverages precedent data from first-generation ADCs to guide its development strategy, aiming for improvements and differentiation in new therapies.
• Research Focus: The company’s main development focus is on ADC therapies and related oncology assets, with efforts to demonstrate competitive differentiation versus first-generation ADCs. Management’s strategy involves benchmarking against existing ADCs and targeting expansion opportunities.
• Talent Retention: The ability to retain key professionals and attract additional qualified staff is highlighted as a critical factor for ongoing success.

Price-Sensitive Information for Shareholders

• Strategic Partnerships: The company’s intent to pursue and potentially execute new strategic partnerships or business development transactions could significantly impact the portfolio value and future growth prospects. Any upcoming announcements regarding partnerships or asset acquisitions may be price-sensitive.
• Financial Position: The management’s assessment that current financial resources are adequate for ongoing operations is reassuring, but any changes in funding needs or capital requirements (for example, due to accelerated R&D or commercialization efforts) could move share prices.
• Regulatory Compliance: Whitehawk has not reported any restatements, error corrections, or regulatory compliance issues, which supports shareholder confidence in financial disclosures.
• SEC Compliance and Governance: The company has filed all required reports, maintained compliance with Sarbanes-Oxley internal control requirements, and has not been subject to any legal proceedings, mine safety disclosures, or foreign jurisdiction inspection barriers, all of which reinforce its operational stability.

Risks and Uncertainties

The report emphasizes that forward-looking statements are subject to risks, uncertainties, and other factors, including those listed in the risk factors section. These can affect actual results and may cause deviations from projections. Investors are cautioned not to place undue reliance on these statements.

Notable Items for Investors

• FYARRO Business: The company’s commercial sale of FYARRO and its ongoing development efforts for ADC therapies are central to its business strategy.
• Market Value: The aggregate market value of voting and non-voting common equity held by non-affiliates, based on NASDAQ closing price as of June 30, 2025, was noted (exact value not specified in the provided excerpt).
• No Major Legal or Regulatory Events: There are no reported legal proceedings, safety disclosures, or regulatory errors that would negatively impact the company’s share value.
• Proxy Statement Incorporation: Portions of the definitive Proxy Statement for the 2026 Annual Meeting will be incorporated by reference, which may include further details on governance and executive compensation.

Sections of Note for Shareholders

1. Business Description
2. Cybersecurity
3. Properties
4. Legal Proceedings
5. Market for Equity and Related Stockholder Matters
6. Management’s Discussion and Analysis
7. Financial Statements and Supplementary Data
8. Director, Officer, and Governance Information
9. Executive Compensation
10. Principal Accountant Fees and Services

Conclusion

Whitehawk Therapeutics, Inc. remains committed to advancing its ADC portfolio, maintaining strategic partnerships, and ensuring financial stability. Investors should closely monitor future announcements related to asset development, partnerships, and funding, as these could materially impact share value.

Disclaimer: This article is a summary and analysis of Whitehawk Therapeutics, Inc.’s 2025 Annual Report and does not constitute investment advice. Investors should review the full SEC filing and consult with a qualified financial advisor before making any investment decisions. Forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those projected.

View Whitehawk Therapeutics, Inc. Historical chart here